| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2018-09-28 | KSQ Therapeutics (USA - MA) | $80 million | series C financing round | Flagship Pioneering (USA - MA) Polaris Partners (USA - MA) ARCH Venture Partners (USA - IL) Alexandria Equities (USA - CA) Baillie Gifford (UK) Cowen Healthcare Investments (USA - NY) Invus (USA - NY) Lilly Asia Ventures (China) | Cancer - Oncology - Immunological diseases - Rare diseases | Series C financing round |
| 2018-09-26 | Minoryx Therapeutics (Spain) | €21.3 million | series B financing round | Chiesi Ventures (Italy) Caixa Capital Risc (Spain) HealthEquity (Spain) Fund+ (Belgium) Idinvest Partners (France) Kurma Partners (France) Sambrinvest (Belgium) Kurma Partners (France) Ysios Capital (Spain) SFPI-FPIM, S.R.I.W | Rare diseases | Series B financing round |
| 2018-09-20 | Fate Therapeutics (USA - CA) | private placement | Cancer - Oncology - Immunological diseases | Private placement | ||
| 2018-09-20 | Y-mAbs Therapeutics (USA - NY) | IPO | Cancer - Oncology | IPO | ||
| 2018-09-12 | CODA Biotherapeutics (USA - CA) | $19 million | series A financing round | MPM Capital (USA - MA) Versant Ventures (USA - CA) Astellas Venture Management (USA - CA) Novartis (Switzerland) | Neurological diseases - CNS diseases | Series A financing round |
| 2018-09-12 | Exocobio (Republic of Korea) | $27 million | series B financing round | Seven Tree Equity Partners (Republic of Korea) CSQUARED Global Asset Management (Republic of Korea) TS Investment Partners (Dubai) K2 Investment, Intervest (Republic of Korea) KDB Capital (Republic of Korea) Atinum Investment (Republic of Korea) GU Equity Partners (Republic of Korea) QUANTUM Ventures Korea (Republic of Korea) Platinum technology Investment (Republic of Korea) | Autoimmune diseases - Dermatological diseases | Series B financing round |
| 2018-09-11 | ProQR Therapeutics (The Netherlands) | $104.1 million | private placement | Rare diseases - Genetic diseases - Ophtalmological diseases | Private placement | |
| 2018-09-07 | Oasmia Pharmaceutical (Sweden) | SEK 35.2 million | private placement | Cancer - Oncology | Private placement | |
| 2018-09-06 | Twentyeight-Seven Therapeutics (USA - MA) | $65 million | series A financing round | MPM Capital (USA - MA) Novartis Venture Fund (USA - MA) Johnson & Johnson Innovation – JJDC (USA - NJ) Vertex Ventures (USA - CA) Longwood Fund (USA - MA) Astellas Venture Management (USA - CA) | Cancer - Oncology | Series A financing round |
| 2018-09-06 | Allogene Therapeutics (USA - CA) | $120 Million | financing round | Cancer - Oncology | Financing round | |
| 2018-09-05 | Forendo Pharma (Finland) | € 4 million | financing round | Vesalius Biocapital (Luxembourg) | Women health | Financing round |
| 2018-09-05 | Retrophin (USA - CA) | $240 million | private placement | Rare diseases | Private placement | |
| 2018-09-05 | 4D Molecular Therapeutics (USA - CA) | $ 90 million | series B financing round | Viking Global Investors (USA - CT) ArrowMark Partners (USA - CO) Janus Henderson Investors (UK) The Biotechnology Value Fund (USA - CA) MiraeAsset Financial Group (Republic of Korea) Pappas Capital & Chiesi Ventures (USA - NC) Pfizer Ventures (USA - NY) Perceptive Advisors (USA - NY) Ridgeback Capital Investments (USA - NY) CureDuchenne Ventures (USA - CA) Berkeley Catalyst Fund (USA - CA) | Rare diseases - Genetic diseases | Series B financing round |
| 2018-08-31 | Antabio (France) | € 12.5 million | series A financing round | iXO Private Equity (France) IRDI SORIDEC Gestion (France) Galia Gestion (France) Omnes Capital (France) BNP Paribas Développement (France) Sham Innovation Santé (Turenne Capital) (France) and company’s historical investors including former President of OM Pharma Christophe Ricard. | Rare diseases - Infectious diseases | Series A financing round |
| 2018-08-16 | Krystal Biotech (USA - PA) | $10 million | private placement | Frazier Healthcare Partners (USA - WA) | Rare diseases - Genetic diseases | Private placement |
| 2018-08-13 | Orchard Therapeutics (UK) | $150 Million | series C financing round | ArrowMark Partners (USA - CO) Cormorant Asset Management (USA - MA) Foresite Capital (USA - NY) RA Capital Management (USA - MA) Perceptive Advisors (USA - NY) RTW Investments (USA - NY) Venrock (USA - CA) Foresite Capital (USA - NY) Sphera Global Healthcare (Spain) Medison Ventures Driehaus Capital Management (USA - IL) Ghost Tree Capital Group (USA - NY) Temasek (Singpore) Baillie Gifford (UK) Cowen Healthcare (USA - NY) Agent Capital (USA - MA) | Rare diseases - Genetic diseases | Series C financing round |
| 2018-08-09 | Bavarian Nordic (Denmark) | € 30 million | loan | European Investment Bank (EIB) | Infectious diseases | Loan |
| 2018-08-08 | Beigene (China) | $903 million | IPO | Cancer - Oncology | IPO | |
| 2018-08-08 | SQZ Biotech (USA - MA) | $72 million | series C financing round | Everblue Management (USA) Illumina Ventures (USA - CA) Invus (USA - NY) Orient Life (AE) Viva Ventures Biotech Group (USA) Bridger Healthcare Partners (USA) Global Health Science Fund (USA) GV (USA - CA) JDRF T1D Fund, (USA - NY) NanoDimension (USA - CA) Polaris (USA - MA) | Cancer - Oncology - Metabolic diseases | Series C financing round |
| 2018-08-08 | Ambys Medicines (USA - CA) | $60 million | series A financing round | Third Rock Ventures (USA - MA) Takeda Pharmaceutical (Japan) | Liver diseases - Hepatic diseases | Series A financing round |
